Ribo y Madrigal alcanzan un primer hito importante en el avance de nuevas terapias con siRNA para MASH

PartnershipPositive

AI Analysis

Summary

Ribo and Madrigal Pharmaceuticals announced achievement of an initial milestone in developing new siRNA therapies for MASH through their collaboration. The milestone represents progress in the joint development program between the two companies.

Outcome Details

Achieved first milestone in advancing new siRNA therapies for MASH

Importance:6/10

Sentiment:

0.60

partnershipsiRNAMASHcollaborationmilestone

Related Companies

$06938.HK $MDGL

Read the original article

Published by PR Newswire Biotech on July 2, 2026 6:27 AM

Read Original